rucaparib
clovis
['brca', 'brca-p', 'rubraca', 'ovarian', 'rucaparib']
from medpage today: a postmarketing study meant to support the approval of rucaparib (rubraca) in ovarian cancer instead demonstrated worse overall survival (os) for women with recurrent, advanced brca-positive disease initially assigned to the drug. 
The Society of Gynecologic Oncology